Because evidence gaps in idiopathic pulmonary fibrosis research hinder demonstration of antifibrotic therapies’ impact on patient quality of life (QOL), integrating validated health-related QOL measures into trials is urgently needed.
Franco Nicolae Grados Rodriguez
Advertisement
Articles by Franco Nicolae Grados Rodriguez
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol
2
Home-Based Heart Failure Care Shows Comparable Safety to Continued Inpatient Care
3
Cardiology Prices Vary Widely by Insurer and State
4
Voice Biomarkers Show Promise for Asthma, COPD Exacerbation Detection
5